| Nome |
# |
|
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities, file e31e124c-0965-987f-e053-3705fe0a095a
|
430
|
|
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer, file e31e124e-be5a-987f-e053-3705fe0a095a
|
363
|
|
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer., file e31e124d-7808-987f-e053-3705fe0a095a
|
315
|
|
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management, file e31e124d-7fd3-987f-e053-3705fe0a095a
|
307
|
|
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB), file e31e124d-7671-987f-e053-3705fe0a095a
|
289
|
|
Immune characterization of breast cancer metastases: prognostic implications., file e31e124d-5d08-987f-e053-3705fe0a095a
|
258
|
|
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial., file e31e124d-7fd1-987f-e053-3705fe0a095a
|
230
|
|
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial ., file e31e124d-cbc5-987f-e053-3705fe0a095a
|
195
|
|
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer., file e31e124d-ce9b-987f-e053-3705fe0a095a
|
169
|
|
Triple-negative breast cancer: current management and future options., file e31e124e-1a5e-987f-e053-3705fe0a095a
|
166
|
|
Controversies of chemotherapy for the treatment of metastatic breast cancer., file e31e124e-154d-987f-e053-3705fe0a095a
|
159
|
|
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis, file e31e124d-7fcf-987f-e053-3705fe0a095a
|
143
|
|
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype., file e31e124e-7356-987f-e053-3705fe0a095a
|
142
|
|
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial., file e31e124d-cb11-987f-e053-3705fe0a095a
|
131
|
|
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY), file e31e124d-33f2-987f-e053-3705fe0a095a
|
122
|
|
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial, file e31e124f-ec08-987f-e053-3705fe0a095a
|
107
|
|
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y), file e31e124e-a41a-987f-e053-3705fe0a095a
|
105
|
|
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer., file e31e124f-50a8-987f-e053-3705fe0a095a
|
79
|
|
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici, file e31e124a-97dc-987f-e053-3705fe0a095a
|
77
|
|
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER, file e31e124d-351c-987f-e053-3705fe0a095a
|
63
|
|
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies, file 3846a9cf-07f6-4480-a1a6-7c26d292627c
|
47
|
|
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort, file b8c32531-6571-4d6d-a0e9-c0ede51be8f2
|
45
|
|
Detection of microparticles from human red blood cells by multiparametric flow cytometry, file e31e124c-02c3-987f-e053-3705fe0a095a
|
43
|
|
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study., file e31e124f-89bb-987f-e053-3705fe0a095a
|
32
|
|
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS, file e31e124d-30ab-987f-e053-3705fe0a095a
|
29
|
|
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO, file e31e124d-30e4-987f-e053-3705fe0a095a
|
29
|
|
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC)., file e31e124e-7982-987f-e053-3705fe0a095a
|
28
|
|
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial, file e31e1250-9101-987f-e053-3705fe0a095a
|
28
|
|
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY., file e31e124e-9724-987f-e053-3705fe0a095a
|
27
|
|
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY, file e31e124d-3704-987f-e053-3705fe0a095a
|
25
|
|
Pazopanib-Induced Heart Failure In A Metastastic Sarcoma Patient: Between Reversible Side Effect and Efficacy, file e31e124c-032b-987f-e053-3705fe0a095a
|
24
|
|
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA, file e31e124d-3016-987f-e053-3705fe0a095a
|
23
|
|
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS, file e31e124d-3017-987f-e053-3705fe0a095a
|
22
|
|
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE, file e31e124d-3522-987f-e053-3705fe0a095a
|
18
|
|
Primary systemic treatment of operable breast cancer with targeted agents, file e31e124d-32ca-987f-e053-3705fe0a095a
|
16
|
|
VALUTAZIONE DEL RISCHIO DI TOSSICITA’ CARDIACA DI TRASTUZUMAB IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO IN TRATTAMENTO ADIUVANTE, file e31e124d-3519-987f-e053-3705fe0a095a
|
16
|
|
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY, file e31e124d-38aa-987f-e053-3705fe0a095a
|
14
|
|
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY, file e31e124d-3075-987f-e053-3705fe0a095a
|
10
|
|
Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials, file ef346bce-a610-41e3-a74c-0757ab038fe2
|
10
|
|
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma - Results from the Gruppo Oncologico Nord Ovest randomized trial, file 4ad83630-2aa3-40ae-b6b0-34e1c313a502
|
7
|
|
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts, file bf213bec-1647-46b0-a203-20d776629dcd
|
6
|
|
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas, file e31e124b-ffe1-987f-e053-3705fe0a095a
|
6
|
|
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation, file a55a95ed-a644-43ce-83fb-ca95f8a7a816
|
5
|
|
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8), file a7fa9036-72cf-4643-8755-86cf7636b2d5
|
4
|
|
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy, file b90eb385-8b45-4964-9e43-ab89a237165d
|
4
|
|
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC), file c0455a7d-75be-4e41-a009-fe11d544c62d
|
2
|
|
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact, file e31e124c-0494-987f-e053-3705fe0a095a
|
2
|
|
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study, file edcdd8de-215f-49c6-9abb-0985573f6c0d
|
2
|
|
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study, file f800e220-a4de-4bda-9cef-86eb5303726e
|
2
|
|
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer, file 4a2ea6ec-773e-4970-9e24-2fb8547e5f2d
|
1
|
|
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma, file 8e9fbe70-d335-4fe1-96b8-779cb8a1c805
|
1
|
|
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors, file e31e124a-963d-987f-e053-3705fe0a095a
|
1
|
|
Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience, file e31e124a-98a3-987f-e053-3705fe0a095a
|
1
|
|
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer, file e31e124a-af0f-987f-e053-3705fe0a095a
|
1
|
|
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis., file e31e124a-af9d-987f-e053-3705fe0a095a
|
1
|
|
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study, file e31e124b-2edd-987f-e053-3705fe0a095a
|
1
|
|
Timing for starting second line therapy in recurrent ovarian cancer., file e31e124b-2ee2-987f-e053-3705fe0a095a
|
1
|
|
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis, file e31e124b-3439-987f-e053-3705fe0a095a
|
1
|
|
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer, file e31e124c-03e8-987f-e053-3705fe0a095a
|
1
|
|
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer, file e31e124d-766b-987f-e053-3705fe0a095a
|
1
|
|
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study., file e31e124d-80fe-987f-e053-3705fe0a095a
|
1
|
| Totale |
4.388 |
